AVADEL PHARMACEUTICALS PLC — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/4372d318-36de-4ece-8051-c04a3edec90b/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-48.8M | 2024-01-01 – 2024-12-31 | evidence 0001012477-25-000010 |
| FY 2023 | $-160.3M | 2023-01-01 – 2023-12-31 | evidence 0001012477-24-000008 |
| FY 2022 | $-137.5M | 2022-01-01 – 2022-12-31 | evidence 0001012477-23-000009 |
| FY 2021 | $-77.3M | 2021-01-01 – 2021-12-31 | evidence 0001012477-22-000004 |
| FY 2020 | $7.0M | 2020-01-01 – 2020-12-31 | evidence 0001012477-21-000004 |
| FY 2019 | $-33.2M | 2019-01-01 – 2019-12-31 | evidence 0001012477-20-000007 |
| FY 2018 | $-95.3M | 2018-01-01 – 2018-12-31 | evidence 0001012477-19-000002 |
| FY 2017 | $68.3M | 2017-01-01 – 2017-12-31 | evidence 0001012477-18-000008 |
| FY 2016 | $-41.3M | 2016-01-01 – 2016-12-31 | evidence 0001012477-17-000021 |
| FY 2015 | $41.8M | 2015-01-01 – 2015-12-31 | evidence 0001012477-17-000021 |
| FY 2014 | $-85.5M | 2014-01-01 – 2014-12-31 | evidence 0001012477-17-000021 |
| FY 2013 | $-42.9M | 2013-01-01 – 2013-12-31 | evidence 0001144204-14-026504 |
| FY 2012 | $-3.2M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-025123 |
| FY 2011 | $-8.8M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-024442 |
| FY 2010 | $-9.0M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-024442 |
| FY 2009 | $-11.4M | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-024442 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AVADEL PHARMACEUTICALS PLC — all facts · Revenue · Operating Income